
Septerna, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Septerna is a biotechnology company developing small-molecule drugs that target G protein-coupled receptors (GPCRs), using its proprietary platform to identify and design therapies for endocrine, metabolic, and other diseases.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Bhatt ElizabethPresident and COO | Sell | $109K | 2,906at $37.61 | Oct 15, 2026 |
| Bhatt ElizabethPresident and COO | Sell | $40K | 1,094at $36.87 | Oct 15, 2026 |
| Third Rock Ventures V, L.P.Insider | Buy | $7.39M | 147,059at $50.27 | Aug 12, 2026 |
| Third Rock Ventures V, L.P.Insider | Buy | $7K | 141at $51.08 | Aug 12, 2026 |
| Long Daniel D.SVP, Drug Discovery | Sell | $81K | 2,334at $34.68 | Aug 3, 2026 |
| Long Daniel D.SVP, Drug Discovery | Sell | $34K | 1,000at $33.98 | Aug 3, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable SEPN activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.